C4 Therapeutics, Inc.
NASDAQ:CCCCBiotechnology
+$0.08 today
- Market cap
- $325.01M
- Beta
- 2.93
- P/E (TTM)
- -4.9
- EPS (TTM)
- -$0.82
Volume 2.75M
Average 2.76M
CCCC Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
C4 Therapeutics, Inc.NASDAQ: CCCC
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow turns positive
Q1 FY2026 financing cash flow was $462K, compared with -$46K a year earlier. Trailing-twelve-month financing cash flow was $126.91M. Over 3 fiscal years it compounded at +379.4% a year.
Context
- Financing cash flow amounted to 351.6% of revenue in FY2025, up 224.2 pp from a year earlier.
- Financing cash flow increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly financing cash flow holds near $462K or moves back toward the trailing-twelve-month quarterly average of $31.73M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 126.4M USD
- Year-over-year change
- +178.8%
- 4-year CAGR
- -7.3%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 126.4M | +178.8% |
| FY2024 | 2024-12-31 | 45.34M | -0.3% |
| FY2023 | 2023-12-31 | 45.49M | +3865.9% |
| FY2022 | 2022-12-31 | 1.15M | -99.3% |
| FY2021 | 2021-12-31 | 171.4M | — |
Financing Cash Flow vs competitors
How CCCC compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +1085.3% is the 3rd highest of 9, against a peer median of +86.3%.
- Financing cash flow amounts to 364.0% of revenue for CCCC, versus a peer median of 404.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $180.48M USD | +300903.0% | +202.6% | 10116.9% | |
| LTM Mar 2026 | $126.91M USD | +1085.3% | +379.4% | 364.0% | |
| LTM Mar 2026 | $109.5M USD | +6044.6% | -1.3% | — | |
| LTM Mar 2026 | $89.31M USD | +520.7% | -5.8% | 258.5% | |
| LTM Mar 2026 | $27.87M USD | +110.1% | -36.8% | 96.4% | |
| LTM Mar 2026 | $26.83M USD | -17.0% | — | 34.4% | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | $24.21M USD | -50.6% | -7.8% | 1242.3% |
| LTM Mar 2026 | $16.27M USD | +62.5% | -16.5% | 549.9% | |
| LTM Mar 2026 | CHF 1.3M CHF | -109.0% | -9.9% | — | |
| Peer median (excluding CCCC) | — | +86.3% | -7.8% | 404.2% | |
Competitors are the stored peer set for CCCC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (83.89M) | (128.18M) | (132.49M) | (105.32M) | (104.99M) |
| Depreciation & Amortization | 1.49M | 1.68M | 1.88M | 1.82M | 1.96M |
| Deferred Income Tax | 1.88M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 21.51M | 30.02M | 27.24M | 29.66M | 19.1M |
| Change in Working Capital | (30.09M) | (16.78M) | (6.94M) | 7.65M | (29.28M) |
| Accounts Receivables | (1.23M) | 4.24M | (10.33M) | 8.7M | 701K |
| Inventory | (2.63M) | 0 | 0 | 0 | 0 |
| Accounts Payables | (1.18M) | (3.33M) | 273K | (119K) | (468K) |
| Other Working Capital | (25.05M) | (17.69M) | 3.12M | (930K) | (29.52M) |
| Other Non-Cash Items | 2.13M | 7.32M | 3.48M | 1.03M | 14.52M |
| Operating Cash Flow | (86.97M) | (105.94M) | (106.84M) | (65.16M) | (98.69M) |
| Capital Expenditures | (1.28M) | (5.5M) | (1.71M) | (180K) | (607K) |
| Acquisitions (Net) | 188.06M | (63.92M) | 0 | 0 | 0 |
| Purchases of Investments | (537.74M) | (219.53M) | (129.9M) | (284.32M) | (227.07M) |
| Sales of Investments | 349.68M | 283.45M | 289.96M | 233.23M | 219.08M |
| Other Investing Activities | (188.06M) | 63.92M | 0 | 0 | 0 |
| Investing Cash Flow | (189.34M) | 58.42M | 158.35M | (51.27M) | (8.6M) |
| Debt Repayment | 0 | 0 | (12.5M) | 0 | 0 |
| Common Stock Issued | 169.47M | 777K | 57.67M | 44.37M | 126.32M |
| Common Stock Repurchased | 0 | 0 | (110K) | (194K) | (193K) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.94M | 370K | 426K | 1.16M | 274K |
| Financing Cash Flow | 171.4M | 1.15M | 45.49M | 45.34M | 126.4M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (104.9M) | (46.37M) | 97M | (71.09M) | 19.1M |
| Free Cash Flow | (88.24M) | (111.44M) | (108.55M) | (65.34M) | (99.3M) |
C4 Therapeutics, Inc.
NASDAQ:CCCC
Intrinsic Alpha fair value
Locked
Current Price
$2.48
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.